Hormonal

In patients with BMI ≥35 kg/m², improvements in glomerular filtration rate (GFR) are driven by the magnitude of weight loss and baseline renal function, regardless of whether the weight loss is achieved via metabolic and bariatric surgery (MBS) or high-dose GLP-1 agonist therapy.

For obese patients (BMI ≥35) concerned about kidney health, achieving significant weight loss is the key factor for improving glomerular filtration rate (GFR). Both high-dose GLP-1 agonists (like 3mg liraglutide) and bariatric surgery can improve kidney function to a similar degree, provided they result in substantial weight loss. The choice between medication and surgery should be based on patient preference and tolerability, as renal outcomes appear equivalent when weight loss is achieved.